These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 994002)

  • 1. Derivatives of apomorphine and of other N-substituted norapomorphines.
    Atkinson ER; Battista SP; Ary IE; Richardson DG; Harris LS; Dewey WL
    J Pharm Sci; 1976 Nov; 65(11):1682-5. PubMed ID: 994002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emetic activity of N-substituted norapomorphines.
    Atkinson ER; Bullock FJ; Granchelli FE; Archer S; Rosenberg FJ; Teiger DG; Nachod FC
    J Med Chem; 1975 Oct; 18(10):1000-3. PubMed ID: 808605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aporphines. 8. Total synthesis and pharmacological evaluation of (plus or minus)-apomorphine, (plus or minus)-apocodeine, (plus or minus)-N-n-propylnorapomorphine, and (plus or minus)-N-n-propylnorapocodeine.
    Neumeyer JL; Neustadt BR; Oh KH; Weinhardt KK; Boyce CB; Rosenberg FJ; Teiger DG
    J Med Chem; 1973 Nov; 16(11):1223-8. PubMed ID: 4201182
    [No Abstract]   [Full Text] [Related]  

  • 4. Synthesis and dopamine receptor affinities of enantiomers of 2-substituted apomorphines and their N-n-propyl analogues.
    Gao YG; Baldessarini RJ; Kula NS; Neumeyer JL
    J Med Chem; 1990 Jun; 33(6):1800-5. PubMed ID: 1971309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Centrally acting emetics. 6. Derivatives of -naphthylamine and 2-indanamine.
    Cannon JG; Kim JC; Aleem MA
    J Med Chem; 1972 Apr; 15(4):348-50. PubMed ID: 5019548
    [No Abstract]   [Full Text] [Related]  

  • 6. Centrally acting emetics. 5. Preparation and pharmacology of 10-hydroxy-11 methoxyaporphine (isoapocodeine). In vitro enzymatic methylation of apomorphine.
    Cannon JG; Smith RV; Modiri A; Sood SP; Borgman RJ; Aleem MA; Long JP
    J Med Chem; 1972 Mar; 15(3):273-6. PubMed ID: 5059211
    [No Abstract]   [Full Text] [Related]  

  • 7. New 2-thioether-substituted apomorphines as potent and selective dopamine D₂ receptor agonists.
    Reinart R; Gyulai Z; Berényi S; Antus S; Vonk A; Rinken A; Sipos A
    Eur J Med Chem; 2011 Jul; 46(7):2992-9. PubMed ID: 21550699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and pharmacological evaluation of thiazole and isothiazole derived apomorphines.
    Sipos A; Mueller FK; Lehmann J; Berényi S; Antus S
    Arch Pharm (Weinheim); 2009 Oct; 342(10):557-68. PubMed ID: 19714675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological activity of (6aS)-10,11-dihydroxyaporphine, the optical antipode of apomorphine.
    Saari WS; King SW
    J Med Chem; 1973 Feb; 16(2):171-2. PubMed ID: 4683115
    [No Abstract]   [Full Text] [Related]  

  • 10. Synthesis and neuropharmacological characterization of 2-O-substituted apomorphines.
    Sipos A; Csutorás C; Berényi S; Uustare A; Rinken A
    Bioorg Med Chem; 2008 Apr; 16(8):4563-8. PubMed ID: 18313931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1-substituted apomorphines as potent dopamine agonists.
    Reinart-Okugbeni R; Vonk A; Uustare A; Gyulai Z; Sipos A; Rinken A
    Bioorg Med Chem; 2013 Jul; 21(14):4143-50. PubMed ID: 23727194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopaminergic effects of non-hydroxylated rigid analogs of apomorphine.
    Rusterholz DB; Long JP; Flynn JR; Cannon JG; Lee T; Pease JP; Clemens JA; Wong DT; Bymaster FP
    Eur J Pharmacol; 1979 Apr; 55(1):73-82. PubMed ID: 571341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Centrally acting emetics. 7. Hofmann and Emde degradation products of apomorphine.
    Cannon JG; Borgman RJ; Aleem MA; Long JP
    J Med Chem; 1973 Mar; 16(3):219-24. PubMed ID: 4738980
    [No Abstract]   [Full Text] [Related]  

  • 14. [Neuropsychotropic activity and toxicity of oxidation products of apomorphine].
    Rehse K; Piesker G; Horowski R
    Arch Pharm (Weinheim); 1978 Apr; 311(4):360-3. PubMed ID: 655808
    [No Abstract]   [Full Text] [Related]  

  • 15. Synthesis and structural requirements of N-substituted norapomorphines for affinity and activity at dopamine D-1, D-2, and agonist receptor sites in rat brain.
    Gao YG; Ram VJ; Campbell A; Kula NS; Baldessarini RJ; Neumeyer JL
    J Med Chem; 1990 Jan; 33(1):39-44. PubMed ID: 2136919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Central mechanisms for apomorphine-induced emesis in the dog.
    Harding RK; Hugenholtz H; Kucharczyk J; Lemoine J
    Eur J Pharmacol; 1987 Nov; 144(1):61-5. PubMed ID: 3436361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apomorphine derivatives and dopaminergic activity.
    Lal S; Sourkes TL
    Adv Neurol; 1974; 5():307-8. PubMed ID: 4474796
    [No Abstract]   [Full Text] [Related]  

  • 18. Centrally acting emetics. II. Norapomorphine and derivatives.
    Koch MV; Cannon JG; Burkman AM
    J Med Chem; 1968 Sep; 11(5):977-81. PubMed ID: 5697109
    [No Abstract]   [Full Text] [Related]  

  • 19. Centrally acting emetics. 8. Conformational aspects of certain dihydrophenanthrene congeners of apomorphine.
    Cannon JG; Smith RV; Aleem MA; Long JP
    J Med Chem; 1975 Jan; 18(1):108-10. PubMed ID: 1109566
    [No Abstract]   [Full Text] [Related]  

  • 20. Diester derivatives as apomorphine prodrugs.
    Borgman RJ; Baldessarini RJ; Walton KG
    J Med Chem; 1976 May; 19(5):717-9. PubMed ID: 944786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.